Abstract
Osteosarcoma (OS) is a rare aggressive bone, presenting low patient survival rate, high metastasis and relapse occurrence, mostly due to multi-drug resistant cells. To surpass that, the use of nanomedicine for the targeted delivery of genetic material, drugs or both have been extensively researched. In this review, we address the current situation of the disorder and some gene therapy options in the nanomedicine field that have been investigated. Among them, polymeric micelles (PM) are an advantageous therapeutic alternative highly explored for OS, as they allow for the targeted transportation of poorly water-soluble drugs to cancer cells. In addition, micelleplexes are PMs with cationic properties with promising features, such as the possibility for a dual therapy, which have made them an attractive research subject. The aim of this review article is to elucidate the application of a micelleplex formulation encapsulating the underexpressed miRNA145 to achieve an active targeting to OS cells and overcome multi-drug resistance, as a new and viable therapeutic strategy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
A chemical law stating that the rate of diffusion observed for a compound in an aqueous solution rises according to the difference in concentration between the two adjoining locations. This difference potentiates the particle movement toward the region with the lowest concentration (Barrera 2005).
References
Abarrategi A, Tornin J, Lucia MC, Hamilton A, Enrique MC, Rodrigo JP, González MV, Baldini N, Garcia-Castro J, Rodriguez R (2016) Osteosarcoma: cells-of-origin, cancer stem cells, and targeted therapies. Stem Cells Int. https://doi.org/10.1155/2016/3631764
Abello J, Nguyen TDT, Marasini R, Aryal S, Weiss ML (2019) Biodistribution of gadolinium- and near infrared-labeled human umbilical cord mesenchymal stromal cell-derived exosomes in tumor bearing mice. Theranostics 9(8):2325–2345. https://doi.org/10.7150/thno.30030
Ahmad N, Alam MA, Ahmad R, Naqvi AA, Ahmad FJ (2018a) Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer. Artif Cells Nanomed Biotechnol 46(2):432–446. https://doi.org/10.1080/21691401.2017.1324466
Ahmad N, Alam MA, Ahmad R, Umar S, Ahmad FJ (2018b) Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations. J Microencapsul 35(4):327–343. https://doi.org/10.1080/02652048.2018.1485755
Ahmad N, Ahmad R, Ahmad FJ, Ahmad W, Alam MA, Amir M, Ali A (2019a) Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia. Saudi J Biol Sci. https://doi.org/10.1016/j.sjbs.2019.11.008
Ahmad N, Ahmad R, Alam MA et al (2019b) Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles. Int J Biol Macromol 128:825–838. https://doi.org/10.1016/j.ijbiomac.2019.01.142
Alexandridis P, Hatton TA (1995) Poly(ethylene oxide)poly(propylene oxide)poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modeling. Colloids Surf A Physicochem Eng Aspects 96(1–2):1–46. https://doi.org/10.1016/0927-7757(94)03028-X
Aliabadi HM, Lavasanifar A (2006) Polymeric micelles for drug delivery. Expert Opin Drug Deliv 3(1):139–162. https://doi.org/10.1517/17425247.3.1.139
Almeida M, Magalhães M, Veiga F, Figueiras A (2018) Poloxamers, poloxamines and polymeric micelles: definition, structure and therapeutic applications in cancer. J Polym Res. https://doi.org/10.1007/s10965-017-1426-x
Alp E, Çirak T, Demirbilek M, Mustafa T, Güven E (2017) Targeted delivery of etoposide to osteosarcoma cells using poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles. Turk J Biol 41(5):719–733. https://doi.org/10.3906/biy-1612-17
Alvarez-Lorenzo C, Rey-Rico A, Sosnik A, Taboada P, Concheiro A (2010) Poloxamine-based nanomaterials for drug delivery. Front Biosci Elite 2E(2):424–440
Amin MCIM, Butt AM, Amjad MW, Kesharwani P (2017) Polymeric micelles for drug targeting and delivery. Nanotechnology-based approaches for targeting and delivery of drugs and genes. Elsevier Inc., Oxford. https://doi.org/10.1016/B978-0-12-809717-5.00006-3
Ayre A, Kadam V, Dand N, Patel P (2013) Polymeric micelles as a drug carrier for tumor targeting. Chron Young Sci 4(2):94. https://doi.org/10.4103/2229-5186.115544
Barrera E (2005) On the sesquicentennial of Fick’s laws of diffusion. Nat Struct Mol Biol 12(4):280. https://doi.org/10.1038/nsmb0405-280
Bielack SS, Werner M, Tunn PU et al (2015) Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol 33(20):2279–2287. https://doi.org/10.1200/JCO.2014.60.0734
Bodratti AM, Alexandridis P (2018) Formulation of poloxamers for drug delivery. J Funct Biomater. https://doi.org/10.3390/jfb9010011
Caffery B, Lee JS, Alexander-Bryant AA (2019) Vectors for glioblastoma gene therapy: viral & non-viral delivery strategies. Nanomaterials. https://doi.org/10.3390/nano9010105
Caliskan Y, Dalgic AD, Gerekci S, Gulec EA, Tezcaner A, Ozen C Keskin D (2019) A new therapeutic combination for osteosarcoma: Gemcitabine and Clofazimine co-loaded liposomal formulation. Int J Pharm 557:97–104. https://doi.org/10.1016/j.ijpharm.2018.12.041
Chaiyawat P, Pruksakorn D, Pipatwattana P, Phanphaisarn A, Teeyakasem P, Klangjorhor J, Settakorn J (2019) Endoplasmic reticulum protein 29 (ERp29) as a novel prognostic marker and tumor suppressor in osteosarcoma. J Bone Oncol. https://doi.org/10.1016/j.jbo.2019.100233
Chen B, Huang Z, Zhang Y, Chen Y, Li Z (2015) MicroRNA-145 suppresses osteosarcoma metastasis via targeting MMP16. Cell Physiol Biochem 37(6):2183–2193. https://doi.org/10.1159/000438575
Choong PFM, Broadhead ML, Clark JCM, Myers DE, Dass CR (2011) The molecular pathogenesis of osteosarcoma: a review. Sarcoma. https://doi.org/10.1155/2011/959248
Chow EKH, Ho D (2013) Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med 5(216):1–12. https://doi.org/10.1126/scitranslmed.3005872
Cottrell J (2018) A review of osteosarcoma therapeutics. J Cancer Treat Diagn 2(2):21–29. https://doi.org/10.29245/2578-2967/2018/2.1127
Cui SY, Wang R, Chen LB (2014) MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med 18(10):1913–1926. https://doi.org/10.1111/jcmm.12358
Deshmukh AS, Chauhan PN, Noolvi MN et al (2017) Polymeric micelles: basic research to clinical practice. Int J Pharm 532(1):249–268. https://doi.org/10.1016/j.ijpharm.2017.09.005
Duchi S, Sotgiu G, Lucarelli E et al (2013) Mesenchymal stem cells as delivery vehicle of porphyrin loaded nanoparticles: effective photoinduced in vitro killing of osteosarcoma. J Control Rel 168(2):225–237. https://doi.org/10.1016/j.jconrel.2013.03.012
Fan L, Wu Q, Xing X, Wei Y, Shao Z (2012) MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochimica et Biophysica Sinica 44(5):407–414. https://doi.org/10.1093/abbs/gms019
Fang X, Bin Zhang JM, Xie X, Liu D, He CW, Wan JB, Chen MW (2016) pH-sensitive micelles based on acid-labile pluronic F68-curcumin conjugates for improved tumor intracellular drug delivery. Int J Pharm 502(1–2):28–37. https://doi.org/10.1016/j.ijpharm.2016.01.029
Fang Z, Sun Y, Xiao H et al (2017) Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle. Biomed Pharmacother 85:160–168. https://doi.org/10.1016/j.biopha.2016.11.132
Feng H, Chu D, Li Z et al (2018) A DOX-loaded polymer micelle for effectively inhibiting cancer cells. RSC Adv 8(46):25949–25954. https://doi.org/10.1039/c8ra04089c
Feng S, Wu ZX, Zhao Z et al (2019) Engineering of bone- and CD44-dual-targeting redox-sensitive liposomes for the treatment of orthotopic osteosarcoma. ACS Appl Mater Interfaces 11(7):7357–7368. https://doi.org/10.1021/acsami.8b18820
Gáscon AR, del Pozo-Rogríguez A, Solinís MÁ (2013) Non-viral delivery systems in gene therapy. Intech. https://doi.org/10.5772/52704
Gazzano E, Buondonno I, Marengo A et al (2019) Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. Cancer Lett 456(April):29–39. https://doi.org/10.1016/j.canlet.2019.04.029
Giansanti L, Condello M, Altieri B, Galantini L, Meschini S, Mancini G (2019) Influence of lipid composition on the ability of liposome loaded voacamine to improve the reversion of doxorubicin resistant osteosarcoma cells. Chem Phys Lipids. https://doi.org/10.1016/j.chemphyslip.2019.05.006
Gigout A, Buschmann MD, Jolicoeur M (2008) The fate of Pluronic F-68 in chondrocytes and CHO clls. Biotechnol Bioeng 100(5):975–987. https://doi.org/10.1002/bit.21840
Gill DR, Pringle IA, Hyde SC (2009) Progress and prospects: the design and production of plasmid vectors. Gene Ther 16(2):165–171. https://doi.org/10.1038/gt.2008.183
Gui K, Zhang X, Chen F et al (2019) Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells. Biomed Pharmacother 111:751–764. https://doi.org/10.1016/j.biopha.2018.11.118
Hang JF, Chen PCH (2014) Parosteal osteosarcoma. Arch Pathol Lab Med 138(5):694–699. https://doi.org/10.5858/arpa.2013-0030-RS
Hardee CL, Arévalo-Soliz LM, Hornstein BD, Zechiedrich L (2017) Advances in non-viral DNA vectors for gene therapy. Genes. https://doi.org/10.3390/genes8020065
Hejazi R, Amiji M (2003) Chitosan-based gastrointestinal delivery systems. J Control Rel 89(2):151–165. https://doi.org/10.1016/S0168-3659(03)00126-3
HiMedia Laboratories Pvt Ltd. (2019) Pluronic (R) F-68: product information, 400086. https://himedialabs.com/TD/TC222.pdf. Accessed 25 Sep 2019
Hong W, Chen D, Zhang X, Zeng J, Hu H, Zhao X, Qiao M (2013) Reversing multidrug resistance by intracellular delivery of Pluronic® P85 unimers. Biomaterials 34(37):9602–9614. https://doi.org/10.1016/j.biomaterials.2013.08.032
Hong ES, Burkett SS, Morrow J et al (2015) Characterization of the metastatic phenotype of a panel of established osteosarcoma cells. Oncotarget 6(30):29469–29481. https://doi.org/10.18632/oncotarget.5177
Hosseinzadeh H, Atyabi F, Dinarvand R, Ostad SN (2012) Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study. Int J Nanomed 7:1851–1863. https://doi.org/10.2147/IJN.S26365
Hsu HK, Hsu KH, Cheng YM, Suen HY, Peng SF (2018) Development and in vitro evaluation of linear PEI-shelled heparin/berberine nanoparticles in human osteosarcoma U-2 OS cells. Molecules (Basel, Switzerland). https://doi.org/10.3390/molecules23123121
Hu H, Zhang Y, Cai XH, Huang JF, Cai L (2012) Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts. Oncol Lett 4(5):1037–1042. https://doi.org/10.3892/ol.2012.866
Kedar U, Phutane P, Shidhaye S, Kadam V (2010) Advances in polymeric micelles for drug delivery and tumor targeting. Nanomed Nanotechnol Biol Med 6(6):714–729. https://doi.org/10.1016/j.nano.2010.05.005
Kesharwani SS, Kaur S, Tummala H, Sangamwar AT (2018) Overcoming multiple drug resistance in cancer using polymeric micelles. Expert Opin Drug Deliv 15(11):1127–1142. https://doi.org/10.1080/17425247.2018.1537261
Kumar VS, Barwar N, Khan SA (2014) Surface osteosarcomas: diagnosis, treatment and outcome. Indian J Orthop 48(3):255–261. https://doi.org/10.4103/0019-5413.132503
Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW (2016) Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 3:16034. https://doi.org/10.1038/mtm.2016.34
Kuo TT, Wang CH, Wang JY, Chiou HJ, Fan CH, Yeh CK (2019) Concurrent osteosarcoma theranostic strategy using contrast-enhanced ultrasound and drug-loaded bubbles. Pharmaceutics. https://doi.org/10.3390/pharmaceutics11050223
Lee HY, Mohammed KA, Nasreen N (2016) Nanoparticle-based targeted gene therapy for lung cancer. Am J Cancer Res 6(5):1118–1134
Lei P, Xie J, Wang L, Yang X, Dai Z, Hu Y (2014) microRNA-145 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1. Mol Med Rep 10(1):155–160. https://doi.org/10.3892/mmr.2014.2195
Lewis VO, Devarajan E, Cardó-Vila M et al (2017) BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation. Proc Natl Acad Sci USA 114(30):8065–8070. https://doi.org/10.1073/pnas.1704173114
Li CJ, Liu XZ, Zhang L, Chen LB, Shi X, Wu SJ, Zhao JN (2016a) Advances in bone-targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma. Orthop Surg 8(2):105–110. https://doi.org/10.1111/os.12238
Li Y, Liu J, Liu ZZ, Wei WB (2016b) MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6. Eur Rev Med Pharmacol Sci 20(24):5117–5125
Li S, Xiong Y, Zhang X (2017) Poloxamer surface modified trimethyl chitosan nanoparticles for the effective delivery of methotrexate in osteosarcoma. Biomed Pharmacother 90:872–879. https://doi.org/10.1016/j.biopha.2017.04.004
Liang W, Gong H, Yin D, Lu S, Fu Q (2011) High-molecular-weight polyethyleneimine conjuncted pluronic for gene transfer agents. Chem Pharm Bull 59(9):1094–1101. https://doi.org/10.1248/cpb.59.1094
Liang C, Li F, Wang L et al (2017) Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials 147:68–85. https://doi.org/10.1016/j.biomaterials.2017.09.015
Lindsey BA, Markel JE, Kleinerman ES (2017) Osteosarcoma overview. Rheumatol Ther 4(1):25–43. https://doi.org/10.1007/s40744-016-0050-2
Lu HH, Huang CH, Shiue TY, Wang FS, Chang KK, Chen Y, Peng CH (2019) Erratum: highly efficient gene release in spatiotemporal precision approached by light and pH dual responsive copolymers. Chem Sci 10(1):284–292. https://doi.org/10.1039/C8SC01494A
Lundstrom K (2018) Viral vectors in gene therapy. Diseases. https://doi.org/10.3390/diseases6020042
Lundstrom K, Boulikas T (2003) Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat 2(5):471–485. https://doi.org/10.1177/153303460300200513
Luo Z, Li D, Luo X, Li L, Gu S, Yu L, Ma Y (2018) Curcumin may serve an anticancer role in human osteosarcoma cell line U-2 OS by targeting ITPR1. Oncol Lett 15(4):5593–5601. https://doi.org/10.3892/ol.2018.8032
Magalhães M, Almeida M, Tavares-da-Silva E et al (2018a) miR-145-loaded micelleplexes as a novel therapeutic strategy to inhibit proliferation and migration of osteosarcoma cells. Eur J Pharm Sci 123(July):28–42. https://doi.org/10.1016/j.ejps.2018.07.021
Magalhães M, Figueiras A, Veiga F (2018b) Smart micelleplexes: an overview of a promising and potential nanocarrier for alternative therapies. Des Dev N Nanocarr. https://doi.org/10.1016/b978-0-12-813627-0.00007-7
Mahmud A, Xiong XB, Aliabadi HM, Lavasanifar A (2007) Polymeric micelles for drug targeting. J Drug Targ 15(9):553–584. https://doi.org/10.1080/10611860701538586
Malhas AM, Sumathi VP, James SL et al (2012) Low-grade central osteosarcoma: a difficult condition to diagnose. Sarcoma. https://doi.org/10.1155/2012/764796
Maloney CW, Edelman M, Symons M, Steinberg BM, Soffer SZ (2017) Gefitinib blocks macrophage-promoted invasion of osteosarcoma via inhibition of receptor-interacting protein kinase 2 (RIPK2) and prevents progression of pulmonary micrometastases. J Am Coll Surg 225(4):S150. https://doi.org/10.1016/j.jamcollsurg.2017.07.337
Maran A, Yaszemski MJ, Kohut A, Voronov A (2016) Curcumin and osteosarcoma: can invertible polymeric micelles help? Materials 9(7):10–13. https://doi.org/10.3390/ma9070520
Marina NM, Smeland S, Bielack SS et al (2016) Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 17(10):1396–1408. https://doi.org/10.1016/S1470-2045(16)30214-5
Martin JW, Squire JA, Zielenska M (2012) The genetics of osteosarcoma. Sarcoma 2012:11. https://doi.org/10.1155/2012/627254
Mazzoni E, Benassi MS, Corallini A et al (2015) Significant association between human osteosarcoma and Simian virus 40. Cancer 121(5):708–715. https://doi.org/10.1002/cncr.29137
Mekhail GM, Kamel AO, Awad GAS, Mortada ND, Rodrigo RL, Spagnuolo PA, Wettig SD (2016) Synthesis and evaluation of alendronate-modified gelatin biopolymer as a novel osteotropic nanocarrier for gene therapy. Nanomedicine 11(17):2251–2273. https://doi.org/10.2217/nnm-2016-0151
Misaghi A, Goldin A, Awad M, Kulidjian AA (2018) Osteosarcoma: a comprehensive review. Sicot-J 4:12. https://doi.org/10.1051/sicotj/2017028
Moghimi SM, Hunter AC (2000) Poloxamers and poloxamines in nanoparticleengineering and experimental medicine. Science 18(October):2958–2964
Moloughney JG, Weisleder N (2013) Poloxamer 188 (P188) as a membrane resealing reagent in biomedical applications. Recent Patents Biotechnol 6(3):200–211. https://doi.org/10.2174/1872208311206030200
Moriarity BS, Otto GM, Rahrmann EP et al (2015) A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet 47(6):615–624. https://doi.org/10.1038/ng.3293.A
Murphy PR, MacFarlane LA (2010) MicroRNA: biogenesis, function and role in cancer. Curr Genom 11(7):537–561
Namee NM (1870) O’Driscoll L (2018) Extracellular vesicles and anti-cancer drug resistance. Biochimi Biophys Acta Rev Cancer 2:123–136. https://doi.org/10.1016/j.bbcan.2018.07.003
Nguyen HK, Lemieux P, Vinogradov SV et al (2000) Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther 7(2):126–138. https://doi.org/10.1038/sj.gt.3301052
O’Day K, Gorlick R (2009) Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 9(4):511–523. https://doi.org/10.1586/ERA.09.7
Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE (2010) Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 27(12):2569–2589. https://doi.org/10.1007/s11095-010-0233-4
Othayoth R, Kumar KS, Karthik V (2013) Development and characterization of chitosan-pluronic polymeric nanoparticles for the breast cancer treatment. Int J Mech Eng Robot 1(1):71–79
Patterson LA, Greer RO, Howard D (1990) Periosteal osteosarcoma of the maxilla: a case report and review of literature. J Oral Maxillofac Surg 48(5):522–526. https://doi.org/10.1016/0278-2391(90)90246-X
Pereira P, Barreira M, Queiroz JA, Veiga F, Sousa F, Figueiras A (2017) Smart micelleplexes as a new therapeutic approach for RNA delivery. Expert Opin Drug Deliv 14(3):353–371. https://doi.org/10.1080/17425247.2016.1214567
Pitto-Barry A, Barry NPE (2014) Pluronic® block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances. Polym Chem 5(10):3291–3297. https://doi.org/10.1039/c4py00039k
PosthumaDeBoer J, van Royen B, Helder M (2013) Mechanisms of therapy resistance in osteosarcoma: a review. Oncol Discov 1(1):8. https://doi.org/10.7243/2052-6199-1-8
Raimondi L, De Luca A, Costa V et al (2017) Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. Oncotarget 8(59):100831–100851. https://doi.org/10.18632/oncotarget.19852
Ramadurai S, Kohut A, Sarangi NK, Zholobko O, Baulin VA, Voronov A, Keyes TE (2019) Macromolecular inversion-driven polymer insertion into model lipid bilayer membranes. J Colloid Interface Sci 542:483–494. https://doi.org/10.1016/j.jcis.2019.01.093
Ramamoorth M, Narvekar A (2015) Non viral vectors in gene therapy—an overview. J Clin Diagn Res 9(1):GE01–GE06. https://doi.org/10.7860/JCDR/2015/10443.5394
Reghupaty SC, Sarkar D (2019) Current status of gene therapy in hepatocellular carcinoma. Cancers. https://doi.org/10.3390/cancers11091265
Rodríguez-Nogales C, González-Fernández Y, Aldaz A, Couvreur P, Blanco-Prieto MJ (2018) Nanomedicines for pediatric cancers. ACS Nano 12(8):7482–7496. https://doi.org/10.1021/acsnano.8b03684
Samal SK, Dash M, Van Vlierberghe S et al (2012) Cationic polymers and their therapeutic potential. Chem Soc Rev 41(21):7147–7194. https://doi.org/10.1039/c2cs35094g
Sampson VB, Yoo S, Kumar A, Vetter NS, Kolb EA, Yustein J (2015) MicroRNAs and potential targets in osteosarcoma: review. Front Pediatr 3(August):1–13. https://doi.org/10.3389/fped.2015.00069
Santander-Ortega MJ, Jódar-Reyes AB, Csaba N, Bastos-González D, Ortega-Vinuesa JL (2006) Colloidal stability of Pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. J Colloid Interface Sci 302(2):522–529. https://doi.org/10.1016/j.jcis.2006.07.031
Saravanabhavan SS, Rethinasabapathy M, Zsolt S et al (2019) Graphene oxide functionalized with chitosan based nanoparticles as a carrier of siRNA in regulating Bcl-2 expression on Saos-2 & MG-63 cancer cells and its inflammatory response on bone marrow derived cells from mice. Mater Sci Eng C 99:1459–1468. https://doi.org/10.1016/j.msec.2019.02.047
Savvidou OD, Bolia IK, Chloros GD, Goumenos SD, Sakellariou VI, Galanis EC, Papagelopoulos PJ (2016) Applied nanotechnology and nanoscience in orthopedic oncology. Orthopedics 39(5):280–286. https://doi.org/10.3928/01477447-20160823-03
Shi J, Kantoff P, Wooster R, Farokhzad O (2017) Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 17(1):20–37. https://doi.org/10.1038/nrc.2016.108
Sinclair A, Islam S, Jones S (2018) Gene therapy: an overview of approved and pipeline technologies. Cadth Issues Emerg Health Technol 171:1–23
Smeester BA, Moriarity BS, Beitz AJ (2017) Osteosarcomagenesis: biology, development, metastasis, and mechanisms of pain. Osteosarcoma Biol Behav Mech i:21. https://doi.org/10.5772/67070
Susa M, Iyer AK, Ryu K et al (2010) Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One. https://doi.org/10.1371/journal.pone.0010764
Tan ML, Choong PFM, Dass CR (2009) Osteosarcoma: conventional treatment vs. gene therapy. Cancer Biol Ther 8(2):106–117. https://doi.org/10.4161/cbt.8.2.7385
Tang S, Yin Q, Su J et al (2015) Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β-amino ester) nanoparticles co-delivering two siRNA and paclitaxel. Biomaterials 48:1–15. https://doi.org/10.1016/j.biomaterials.2015.01.049
Tharmalingam T, Ghebeh H, Wuerz T, Butler M (2008) Pluronic enhances the robustness and reduces the cell attachment of mammalian cells. Mol Biotechnol 39(2):167–177. https://doi.org/10.1007/s12033-008-9045-8
Gene Therapy Products on the Market. (n.d.) Gene therapy net. https://www.genetherapynet.com/gene-therapy-products-on-the-market.html. Accessed 24 Sep 2019
Tirino V, Desiderio V, Paino F et al (2011) Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 25(6):2022–2030. https://doi.org/10.1096/fj.10-179036
Tong R, Kohane DS (2016) New strategies in cancer nanomedicine. Annu Rev Pharmacol Toxicol 56(1):41–57. https://doi.org/10.1146/annurev-pharmtox-010715-103456
Torreggiani E, Roncuzzi L, Perut F, Zini N, Baldini N (2016) Multimodal transfer of MDR by exosomes in human osteosarcoma. Int J Oncol 49(1):189–196. https://doi.org/10.3892/ijo.2016.3509
Wakaskar RR (2017) Passive and active targeting in tumor microenvironment. Int J Drug Dev Res 9(2):37–41
Wang F, Pang JD, Huang LL et al (2018) Nanoscale polysaccharide derivative as an AEG-1 siRNA carrier for effective osteosarcoma therapy. Int J Nanomed 13:857–875. https://doi.org/10.2147/IJN.S147747
Wang J, Wang F, Li X, Zhou Y, Wang H, Zhang Y (2019) Uniform carboxymethyl chitosan-enveloped Pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound. Colloids Surf B Biointerfaces 177:425–432. https://doi.org/10.1016/j.colsurfb.2019.02.028
Wicki A, Witzigmann D, Balasubramanian V, Huwyler J (2015) Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Controll Rel 200:138–157. https://doi.org/10.1016/j.jconrel.2014.12.030
Williams PD, Kingston PA (2011) Plasmid-mediated gene therapy for cardiovascular disease. Cardiovasc Res 91(4):565–576. https://doi.org/10.1093/cvr/cvr197
Worgall S, Crystal RG (2007) Gene therapy. Oncology nursing, 4th edn. Elsevier, Oxford. https://doi.org/10.5005/jp/books/10569_34
Wu G, Yu W, Zhang M, Yin R, Wu Y, Liu Q (2018) MicroRNA-145-3p suppresses proliferation and promotes apotosis and autophagy of osteosarcoma cell by targeting HDAC4. Artif Cells Nanomed Biotechnol 46(sup2):579–586. https://doi.org/10.1080/21691401.2018.1464459
Xie B, Li Y, Zhao R et al (2018) Identification of key genes and mirnas in osteosarcoma patients with chemoresistance by bioinformatics analysis. BioMed Res Int 2018:10. https://doi.org/10.1155/2018/4761064
Yang F, Wen X, Ke QF, Xie XT, Guo YP (2018) pH-responsive mesoporous ZSM-5 zeolites/chitosan core-shell nanodisks loaded with doxorubicin against osteosarcoma. Mater Sci Eng C 85:142–153. https://doi.org/10.1016/j.msec.2017.12.024
Yin JQ, Fu YW, Xie XB et al (2018) Telangiectatic osteosarcoma: outcome analyses and a diagnostic model for differentiation from aneurysmal bone cyst. J Bone Oncol 11:10–16. https://doi.org/10.1016/j.jbo.2017.11.003
Yu W, Ye M, Zhu J et al (2018) Zinc phthalocyanine encapsulated in polymer micelles as a potent photosensitizer for the photodynamic therapy of osteosarcoma. Nanomed Nanotechnol Biol Med 14(4):1099–1110. https://doi.org/10.1016/j.nano.2018.02.005
Zhang Y, Huang Y, Li S (2014) Polymeric micelles: Nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech 15(4):862–871. https://doi.org/10.1208/s12249-014-0113-z
Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH, Wang WJ (2015) MicroRNAs in osteosarcoma. Clin Chim Acta 444:9–17. https://doi.org/10.1016/j.cca.2015.01.025
Zhang Y, Buhrman JS, Liu Y, Rayahin JE, Gemeinhart RA (2016) Reducible micelleplexes are stable systems for anti-miRNA delivery in cerebrospinal fluid. Mol Pharm 13(6):1791–1799. https://doi.org/10.1021/acs.molpharmaceut.5b00933
Zhang X, Xu ZH, Xie H, Sun YW, Liu J, Zhao YB (2018) ING5 is a potential target for osteosarcoma therapy. Technol Cancer Res Treat 17:1–5. https://doi.org/10.1177/1533033818762680
Zhao L, Bi D, Qi X, Guo Y, Yue F, Wang X, Han M (2019) Polydopamine-based surface modification of paclitaxel nanoparticles for osteosarcoma targeted therapy. Nanotechnology 30(25):255101. https://doi.org/10.1088/1361-6528/ab055f
Zhou G, Shi X, Zhang J, Wu S, Zhao J (2013) MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review. J Int Med Res 41(1):1–12. https://doi.org/10.1177/0300060513475959
Acknowledgements
The present work was financially supported by National Funds (FCT/MEC, Fundação para a Ciência e Tecnologia/Ministério da Educação e Ciência) through project UID/QUI/50006/2013 and co-financed by the European Union (FEDER under the Partnership Agreement PT2020). Additionally, it was financed by the FCT PTDC/BTM-MAT/30255/2017 grant (POCI-01-0145-FEDER-030255) from the Portuguese Foundation for Science and Technology (FCT) as well as the European Community Fund (FEDER) by the COMPETE2020 program.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest regarding the publication of this review.
Rights and permissions
About this article
Cite this article
Melim, C., Jarak, I., Veiga, F. et al. The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease. 3 Biotech 10, 147 (2020). https://doi.org/10.1007/s13205-020-2142-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-020-2142-5